A Phase II Study of Vorinostat (MK-0683) in Patients with Polycythemia Vera and Essential Thrombocythemia
Christen Lykkegaard Andersen(Copenhagen University Hospital), Hans Carl Hasselbalch(Zealand University Hospital), Elisabeth Ejerblad(Uppsala University), Savio Fernandes(Russells Hall Hospital), Tobias Wirenfeldt Klausen(Copenhagen University Hospital), Eva Löfvenberg(Karolinska University Hospital), Torben Mourits‐Andersen(Hospital South West Jutland), Claire Harrison(Guy's and St Thomas' NHS Foundation Trust), Jan Samuelsson(Karolinska University Hospital), Hanne Vestergaard(Odense University Hospital), Björn Andréasson(NU Hospital Group), Mary Frances McMullin(Queen's University Belfast), D. Bareford(Birmingham City Hospital), Olle Linder(Örebro University Hospital), Sonja Zweegman(Vrije Universiteit Amsterdam), Erik Ahlstrand(Örebro University), Ole Weis Bjerrum(Rigshospitalet), Steven Knapper(Cardiff University), Herdis Larsen(Regionshospitalet Viborg), Morten K. Jensen(Aarhus University Hospital)
Cited by 6
Related Papers
Somatic <i>CALR</i> Mutations in Myeloproliferative Neoplasms with Nonmutated <i>JAK2</i>
|New England Journal of Medicine|2013|1.7k
Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial
|The Lancet|2020|1.2k
Immunohistochemical Double-Hit Score Is a Strong Predictor of Outcome in Patients With Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone
|Journal of Clinical Oncology|2012|682
The Duration of Oral Anticoagulant Therapy after a Second Episode of Venous Thromboembolism
|New England Journal of Medicine|1997|611